復星醫藥(600196.SH):復宏漢霖擬於上交所科創板上市
格隆匯3月30日丨復星醫藥(600196.SH)公佈,2020年3月30日,公司第八屆董事會第十二次會議審議通過了《關於控股子公司上海復宏漢霖生物技術股份有限公司至上海證券交易所科創板上市方案的議案》等事項,同意並提請股東大會批准上海復宏漢霖生物技術股份有限公司(以下簡稱“復宏漢霖”)於境內首次公開發行人民幣普通股(A股)並在上交所科創板上市交易。
根據復宏漢霖的實際情況,本次發行的募集資金扣除發行費用後,初步考慮用於生物類似藥及創新藥研發項目、生物醫藥產業化基地項目以及補充營運資金(以下簡稱“募集資金投資項目”)。復宏漢霖可根據市場條件、政策調整及監管機構的意見,對募集資金投資項目進行具體調整。
集團的主營業務主要涉及藥品製造與研發、醫療器械與醫學診斷、醫療服務、醫藥分銷和零售四大板塊,目前各項業務保持良好的發展趨勢。復宏漢霖專注於單克隆抗體藥物的研發、生產、銷售及其相關技術服務,屬於藥品製造與研發板塊,但其業務領域、運營方式與集團其他業務之間保持較高的獨立性,復宏漢霖科創板上市不會對集團其他業務的持續經營運作構成實質性影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.